Status:
COMPLETED
NPDT Evaluation in Children With CFTR and (PSC)
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborating Sponsors:
Boston Children's Hospital
Conditions:
Primary Sclerosing Cholangitis
Inflammatory Bowel Disease
Eligibility:
All Genders
12+ years
Brief Summary
The investigators hypothesize that PSC in children is associated with mutations and functional changes of the cystic fibrosis (CF) gene.
Detailed Description
The purpose of this protocol is to perform Nasal Transepithelial Potential Difference (NTPD) testing to assess the function of the cystic fibrosis gene product, a chloride channel referred to as CFTR,...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 12 years of age and older
- Must have diagnosis of primary sclerosing cholangitis and/or inflammatory bowel disease
- Absence of other liver disease, such as viral hepatitis, drug-induced liver disease, and metabolic/hereditary liver disease
- No exclusion based on sex, race, and ethnic background
Exclusion
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00179439
Start Date
January 1 2004
End Date
January 1 2006
Last Update
December 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215